Disease · MONDO_0019091
Comparisons in its trials49
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 49
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Hydrocortisone vs Placebo: deaths from any cause | 43 of 398 | 46 of 402 | 800 | NCT01353313 | Trial comparisons |
| Hydrocortisone vs Placebo: serious adverse events | 84 of 398 | 95 of 402 | 800 | NCT01353313 | Trial comparisons |
| BUDE vs SURF: deaths from any cause | 49 of 323 | 42 of 318 | 641 | NCT04545866 | Trial comparisons |
| BUDE vs SURF: serious adverse events | 63 of 323 | 55 of 318 | 641 | NCT04545866 | Trial comparisons |
| Inhaled Nitric Oxide (iNO) vs Placebo (Nitrogen): Necrotizing Enterocolitis (NEC) | 5 of 59 | 10 of 65 | 124 | NCT00955487 | Trial comparisons |
| Inhaled Nitric Oxide (iNO) vs Placebo (Nitrogen): Threshold Retinopathy of Prematurity (ROP) | 3 of 59 | 4 of 65 | 124 | NCT00955487 | Trial comparisons |
| Inhaled Nitric Oxide (iNO) vs Placebo (Nitrogen): Symptomatic PDA Requiring Surgical Ligation | 3 of 59 | 8 of 65 | 124 | NCT00955487 | Trial comparisons |
| Inhaled Nitric Oxide (iNO) vs Placebo (Nitrogen): Severe Intracranial Hemorrhage | 2 of 59 | 4 of 65 | 124 | NCT00955487 | Trial comparisons |
| Inhaled Nitric Oxide (iNO) vs Placebo (Nitrogen): Sepsis | 13 of 59 | 14 of 65 | 124 | NCT00955487 | Trial comparisons |
| Inhaled Nitric Oxide (iNO) vs Placebo (Nitrogen): deaths from any cause | 2 of 59 | 4 of 65 | 124 | NCT00955487 | Trial comparisons |
| Inhaled Nitric Oxide (iNO) vs Placebo (Nitrogen): Symptomatic PDA Requiring Medical Treatment | 1 of 59 | 2 of 65 | 124 | NCT00955487 | Trial comparisons |
| Inhaled Nitric Oxide (iNO) vs Placebo (Nitrogen): serious adverse events | 27 of 59 | 42 of 65 | 124 | NCT00955487 | Trial comparisons |
| Azithromycin vs Placebo (5% Dextrose): Number of Participants Who Received Postnatal Steroids | 15 of 60 | 14 of 61 | 121 | NCT01778634 | Trial comparisons |
| Azithromycin vs Placebo (5% Dextrose): Number of Participants With Periventricular Leukomalacia (PVL) | 4 of 60 | 5 of 61 | 121 | NCT01778634 | Trial comparisons |
| Azithromycin vs Placebo (5% Dextrose): Number of Participants With Survival And Transfer From NICU With Microbiological Eradication of Ureaplasma | 55 of 60 | 37 of 61 | 121 | NCT01778634 | Trial comparisons |
| Azithromycin vs Placebo (5% Dextrose): Number of Participants With Cardiac Arrhythmia | 0 of 60 | 0 of 61 | 121 | NCT01778634 | Trial comparisons |
| Azithromycin vs Placebo (5% Dextrose): Number of Participants Who Received Non-Study Antibiotics | 8 of 60 | 14 of 61 | 121 | NCT01778634 | Trial comparisons |
| Azithromycin vs Placebo (5% Dextrose): Number of Participants With Pulmonary Impairment | 15 of 60 | 12 of 61 | 121 | NCT01778634 | Trial comparisons |
| Azithromycin vs Placebo (5% Dextrose): deaths from any cause | 5 of 60 | 6 of 61 | 121 | NCT01778634 | Trial comparisons |
| Azithromycin vs Placebo (5% Dextrose): Number of Participants Who Died | 5 of 60 | 6 of 61 | 121 | NCT01778634 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019091/comparisons